Denali Q2 net income $183M on Biogen opt-in; discontinues DNL919 in Alzheimer's

Denali Therapeutics Inc.

2023-Q2 EPS reported $0.52 revenue$329,264,000

Net income $183.4M (Q2 2022: net loss $58.8M) on $294.1M collaboration revenue from Biogen's ATV:Abeta option.
Discontinued DNL919 (ATV:TREM2) in Alzheimer's due to narrow therapeutic window and evolving treatment landscape.
Biogen exercised option to license ATV-amyloid-beta program; will handle development and commercialization.
Revised BIIB122 (LRRK2) program: focus on LUMA study in Parkinson's; LIGHTHOUSE discontinued, no safety issues.
Cash and marketable securities $1.19B; DNL310 showed ~40-64% NfL reduction in MPS II, IND cleared for DNL126.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Denali Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-23-000119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.